NCT01763788 2019-10-25A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)Eli Lilly and CompanyPhase 1/2 Completed192 enrolled 24 charts